# ANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer

Source: https://onco.cc/trials/nct07444541/  
OnCo record `nct07444541` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Gemcitabine in pancreatic ductal adenocarcinoma, run by Anova Innovation Limited, now recruiting.

## Summary

ANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer is a phase 1/2 interventional study registered as NCT07444541 by Anova Innovation Limited, with 84 participants planned, started 2026-08 and due to reach its primary completion in 2027-08. Interventions recorded: ANO31905, Nanoparticle Albumin-Bound Paclitaxel and Gemcitabine.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07444541
- Phase: 1/2
- Setting: A Phase Ib/Ⅱ Clinical Study to Evaluate the Safety and Efficacy of ANO31905 for Injection in Combination With Chemotherapy as the First-line Treatment for Patients With CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer
- Sponsor: Anova Innovation Limited
- Enrolled: 84

## Sources

- ClinicalTrials.gov NCT07444541: https://clinicaltrials.gov/study/NCT07444541

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- drugs: [Gemcitabine](https://onco.cc/drugs/gemcitabine/)

---
JSON: https://onco.cc/api/v1/entities/nct07444541.json